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Introduction: The aim of this study was to examine the association between mild parkinsonian signs
(MPS), cerebral small-vessel disease (SVD), and total SVD burden in patients with vascular risk factors.
Methods: We performed a cross-sectional study among 268 patients with vascular risk factors but
without parkinsonism or dementia (71.0 ± 7.8 years, 63% male). MPS was evaluated via Uniﬁed Par-
kinson's Disease Rating Scale Part III. Brain MRI was used to determine SVD (cerebral microbleeds
[CMBs], lacunar infarctions [LIs], and white matter hyperintensities [WMH]). The presence of each SVD
feature was indicated by the total SVD score. Logistic regression analyses were performed adjusting for
age, sex, history of stroke, hypertension, diabetes mellitus, and dyslipidemia.
Results: In a multivariate analysis, we found that the presence of CMBs, deep CMBs, mixed (in the basal
ganglia and thalamus) LIs, periventricular hyperintensities (PVH), and deep WMH (DWMH), and total
SVD score were signiﬁcantly associated with MPS, whereas strictly lobar CMBs and other LIs (in strictly
basal ganglia or strictly thalamus) were not. We also found a signiﬁcant association between mixed LIs,
PVH, DWMH and total SVD score and gait/balance function, between PVH and rigidity, and between
mixed LIs and bradykinesia. Among elderly participants (73years), the association of total SVD score,
deep CMBs, mixed LIs, and PVH, with MPS remained signiﬁcant.
Conclusion: Our results provide additional evidence that SVD including CMBs, and especially total SVD
burden, might be a surrogate marker for MPS and support the contribution of hypertensive micro-
angiopathy as the underlying etiology.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cerebral small-vessel disease (SVD) is a leading cause of stroke,
cognitive impairment, gait and balance disturbances, and disability
[1]. Additionally, previous studies demonstrated an association
between SVD, i.e., lacunar infarctions (LIs) and white matter
hyperintensities (WMH), andmild parkinsonian signs (MPS), which
refer to subtle motor disturbances consisting of bradykinesia,
tremor, rigidity, and gait/balance function [2,3]. MPS occur in
15e40% of general elderly population and are associated with, Osaka University Graduate
, 565-0871, Japan.
ac.jp (H. Mochizuki).
Ltd. This is an open access article ufunctional impairment [4]. The mechanism of MPS is heteroge-
neous, not completely understood, and appears to depend in part
on aging, including age-associated decline in the dopaminergic
activity [4]. Moreover, there is an increased awareness of the role
played by not only neurodegenerative pathologies but also vascular
pathology in accelerating MPS [4], with a recent prospective study
raising the possibility that SVD are the initial events in incident
parkinsonism including Parkinson's disease (PD) [5].
These studies suggest that the presence of MPS in the elderly
might reﬂect, in part, the accumulation of vascular pathology
caused by preventable vascular diseases [2,3]. Thus, it might be
useful to identify such a patient for motor impairment at an early
stage using imaging markers.
In this context, cerebral microbleeds (CMBs), among the spec-
trum of SVD, are of particular interest because they frequentlynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Flowchart of patient recruitment in this study.
J. Hatate et al. / Parkinsonism and Related Disorders 26 (2016) 29e3430occur in the elderly population [6]. It is generally considered that
the location of CMBs results from 2 underlying pathologies: deep
CMBs are related to hypertensive vasculopathy, while strictly lobar
CMBs reﬂect cerebral amyloid angiopathy (CAA) [6]. We hypothe-
sized that the presence of CMBs could reﬂect a heavier burden of
hypertensive or CAA pathology, which could increase the risk of
MPS.
Furthermore, although there may be substantial correlations
among these SVD features, it is unclear if SVD is a better predictor of
MPS than its individual components or global SVD burden, i.e., the
combined assessment of total cerebral SVD. Few studies have
investigated the SVD components individually and as a whole. We
therefore investigated the association between MPS and each SVD
feature and total SVD burden in the elderly individuals with
vascular risk factors.
2. Methods
2.1. Patients and evaluation of MPS
We prospectively recruited outpatients from Department of
Neurology and Stroke center at the Osaka University Hospital,
where physicians control risk factors in high-risk patients for pri-
mary and secondary prevention of vascular diseases. Subjects were
older than 50 years with more than one vascular risk factor,
including hypertension, diabetes, dyslipidemia, history of smoking,
and documented history of stroke, coronary artery disease, or, atrial
ﬁbrillation, and enrolled into this study between October 2012 and
December 2013. Patients were excluded from the study if they had
experienced a symptomatic vascular event during the previous 6
months. In addition, those with collagen disease, malignant dis-
ease, and chronic inﬂammatory disease were excluded. At entry,
346 outpatients underwent a baseline clinical assessment including
medical history, pharmacological treatment history, physical and
neurological examination, blood sampling, and brain MRI. We
assessed MPS using the Uniﬁed Parkinson's Disease Rating Scale
(UPDRS) Part III and evaluating 4 categories (bradykinesia, tremor,
rigidity, and gait/balance function) [7]. We identiﬁed patients as
having MPS when they had either (1) 2 or more items with a score
of 1; or (2) 1 item with a score of 2 or greater. Parkinsonism was
deﬁned as patients having 2 or more items with a score of 2 or
greater in 2 or more categories [2,8]. Our intention was to study
patients with earliest or suspected movement impairment, but not
with overt movement impairment. Thus, the eligible participants
basically had no clinically disability on daily life which indicates no
sequelae. The patients with distinct parkinsonian signs were
excluded from the analysis, as they could be considered as un-
identiﬁed prevalent cases of parkinsonism. Brieﬂy, participants
were considered to have PD or parkinson plus syndrome if 1) they
had previously received a diagnosis of PD or parkinson plus syn-
drome, or 2) they hadmet the criteria of parkinsonism in UPDRS. In
addition, cases of PD or parkinson plus syndrome were identiﬁed
taking into account multiple sources. Diagnoses were also sup-
ported by imaging, such as MRI scan or MIBG cardiac scintigraphy,
when available. Furthermore, none of the patients were included
drug-induced parkinsonism. Finally, consensus diagnosis of case
conferences was made by a panel of neurologists.
Consequently, patients who (1) had insufﬁcient MRI data to
evaluate SVD (n ¼ 52), (2) distinct parkinsonian signs (previously
diagnoses with PD [n ¼ 8], or parkinsonism [n ¼ 6]), (3) had
persistent severe hemiplegia (Manual Muscle Testing: 0/5 to 3/5) or
severe spasticity due to stroke history (n ¼ 3), (4) were diagnosed
with depression (n ¼ 4) or dementia (n ¼ 5), which could hinder
the evaluation of MPS, were excluded from the analysis. Finally, all
analyses were based on 268 patients with complete baseline data(Fig. 1). This study was approved by the local ethical review board,
and patients provided written informed consent.2.2. Evaluation of MRIs
MRI was acquired using a single 3.0T scanner. The imaging
protocol included T1-,T2-weighted, ﬂuid attenuated inversion re-
covery (FLAIR), and gradient echo T2*-weighted sequences. The
sequence parameters were as follows:axial images, 22e24; ﬁeld of
view, 201e220 mm; echo time, 10e20 ms; repetition time,
600e800 ms; slice thickness, 5.0 mm; interslice gap, 1.0e1.5 mm.
Structural MRI analysis was performed by a single experienced
observer blinded to clinical data. CMBs were deﬁned as 10 mm of
nodular hypointensity lesions on T2*-weighted images [6]. We
examined CMBs regions by classifying them into strictly lobar
(frontal, parietooccipital, and temporal lobes, and white matter) or
deep (basal ganglia, thalamus, and infratentorial), according to
previous studies [9,10].
LIs was deﬁned from 3 to 15 mm, with a hypointense lesion and
hyperintense rim on FLAIR-images when located supratentorially:
in the subcortical white matter, thalamus, or basal ganglia, ac-
cording to the corresponding hyper- and hypo-intensity on T2-and
T1-images, respectively. For the analyses, patients with both basal
ganglia and thalamus lacunes were pooled in a single category as
mixed LIs. Therefore, we considered the following variables as the
location of LIs: strictly basal ganglia, mixed [basal ganglia and
thalamus], strictly thalamus. WMH were deﬁned as hyperintense
lesions on FLAIR-images, and were scored by the Scheltens and
Fazekas scale [11,12]. In accordance with slightly modiﬁed Schel-
tens scale [11], periventricular hyperintensities (PVH) were evalu-
ated using 3 regions (frontal caps, occipital caps, and lateral bands)
and scored on a scale of 0e2 (range, 0e6). Deep white matter
hyperintensities (DWMH) were evaluated using 4 regions (frontal,
parietal, occipital, and temporal lobe) and scored on a scale of 0e6
(range, 0e24). We also both graded on a scale of 0e3 according to
the Fazekas scale [12].
For the analysis of total SVD severity, based on the recently
described score with slight modiﬁcations [13], we rated the total
SVD burden, by counting the presence of each SVD features (LIs,
CMBs, DWMH, and PVH). The presence of LIs and CMBs were
deﬁned as the presence of 1 LIs (1 point if present) or 1 CMBs (1
point if present). Presence of DWMH was deﬁned as either early
conﬂuent deep WMH (Fazekas score 2 or 3) or irregular PVH
extending into the deep white matter (Fazekas score 3) (1 point if
present). The sum of ratings was used as a total SVD score (range,
J. Hatate et al. / Parkinsonism and Related Disorders 26 (2016) 29e34 310e4) [13].
2.3. Deﬁnition of vascular risk factors
Hypertension was deﬁned as systolic blood pressure
140 mmHg, diastolic blood pressure 90 mmHg, or use of anti-
hypertensive drug. Diabetes mellitus was deﬁned as fasting plasma
glucose level  126 mg/dl, HbA1c (NGSP) level 6.5%, or use of
hypoglycemic drug/insulin injection. Dyslipidemia was deﬁned as
low density lipoprotein cholesterol level 140 mg/dl, high density
lipoprotein cholesterol level40mg/dl, triglyceride level150mg/
dl, or use of hypolipidemic drug. Patients were categorized as
having a history of coronary heart disease (ie, myocardial infarction,
hospitalization for angina pectoris, arterial revascularization pro-
cedure), stroke (ischemic or hemorrhagic), or atrial ﬁbrillation if
they had previously received each diagnosis. Stroke was deﬁned as
an acute disturbance of focal neurological dysfunction with
symptoms and a result of either cerebral infarction or hemorrhage
with imaging evidence. Smoking was evaluated based on current
habits. Body mass index was calculated from height and weight
measured.
2.4. Statistical analysis
The baseline characteristics were presented as number (per-
centage), mean ± standard deviation or median (interquartile), and
compared between patients with MPS and those without MPS by
the c2 test, Student-t test, or ManneWhitney U test. Logistic
regression analysis was used to estimate the association between
MPS and SVD (CMBs [any, deep, and strictly lobar]), LIs [any, strictly
basal ganglia, strictly thalamus, mixed (basal ganglia and thal-
amus)], PVH, DWMH and total SVD: adjusted for age, sex, intervals
of MRI (duration between baseline examination and brain MRI),
hypertension, diabetesmellitus, dyslipidemia, and history of stroke,
which were generally associated with SVD. All these analyses were
repeated to explore the relationships between the 4 categories of
MPS and SVD. Moreover, since aging can considered to be a strong
confounder in the relation between SVD and MPS, we also esti-
mated the association between SVD and MPS, as according to
whether73 years, because themedian age of subjects with MPS is
73 years in our cohort. A two-tailed P value of <0.05 was considered
statistically signiﬁcant. All analyses were performed using JMP pro
11.0 (SAS Institute Inc., Cary, N.C., USA).
3. Results
3.1. Characteristics
The characteristics of participants are shown in Table 1. The
mean age was 71.0 ± 7.8 years, and 63% were male. Eighty-two
percent of subjects in the whole cohort had hypertension, 75%
had dyslipidemia, and 36% had a history of stroke. Among 268
subjects, 58 (21.6%) had 1 CMBs (42 participants [15.7%] deep
CMBs, and 16 [6%] strictly lobar CMBs). LIs were present in 39% (62
[23.1%] strictly basal ganglia,11 [4.1%], strictly thalamus, and 16 [6%]
mixed).
3.2. MPS and SVD
The number of patients who were diagnosed with MPS was 131
(48.8%) (bradykinesia; 31 [11.6%], tremor; 0 [0%], rigidity; 97
[36.2%], and gait/balance impairment; 28 [10.4%]), respectively. In
the univariate analysis (Table 1), patients with MPS were signiﬁ-
cantly older and had a baseline history of stroke, with more severe
SVD (mixed LIs, CMBs, deep CMBs, PVH, DWMH, and total SVDscore) than patients without MPS. In the multivariable analyses
adjusting for age, sex, intervals of MRI, hypertension, diabetes,
dyslipidemia, and history of stroke, we found that CMBs, deep
CMBs, mixed LIs, PVH, DWMH, and total SVD were signiﬁcantly
associated with MPS, whereas the relationship between strictly
lobar CMBs and other LIs (strictly thalamus, or strictly basal
ganglia) and MPS was not signiﬁcant (Fig. 2). Regarding each rele-
vant category, it was difﬁcult to evaluate the category of tremor
because it was absent. Therefore, we investigated the remaining 3
categories. In the multivariable analyses, we found a signiﬁcant
association between mixed LIs, PVH, DWMH, and total SVD score
and gait/balance function, between PVH and rigidity, and between
mixed LIs and bradykinesia (Table 2).
According to whether 73 years, a univariate analysis is shown
in Supplementary Tables. Although no signiﬁcant difference be-
tween age and MPS was observed among patients 73 years, total
SVD score, CMBs, deep CMBs, mixed LIs, or, PVH was signiﬁcantly
associated with MPS (Supplementary Table 1). Subsequently, we
analyzed the risk of MPS via multivariate analysis. Among patients
73 years, the association between total SVD score, deep CMBs,
mixed LIs, and PVH, and MPS remained signiﬁcant. Moreover, total
SVD score, deep CMBs, and WMHs remained signiﬁcant among
patients <73 years (Supplementary Table 2).
4. Discussion
Our results add to the accumulating clinically relevant evidence
that SVD signiﬁcantly contributes to the presence of MPS in pa-
tients with vascular risk factors, independent of age, vascular risk,
and stroke. Deep CMBs, mixed LIs, PVH, as well as, total SVD score
were independently associated with MPS at any age. In particular,
although aging can be considered as a strong confounder in the risk
of both SVD and MPS, we conﬁrmed that the association remained
signiﬁcant among patients 73 years. This suggests that patients
with MPS have indeed a substantial load of SVD, which could be as
potential surrogate marker for MPS.
As commonly observed with LIs and WMH, CMBs may disrupt
the connections of functionally important basal ganglia-
thalamofrontal cortical circuits relevant for MPS, ultimately lead-
ing to the damage of neural networks superimposed to the effects
of other often coexisting SVD. In contrast, we did not identify a
signiﬁcant relationship between MPS and strictly lobar CMBs
(reﬂecting CAA), even in the univariate analysis. This is in line with
an earlier study on the relationship between only deep CMBs and
gait disturbances [14]. Furthermore, deep CMBs were more
frequent than strictly lobar CMBs in patients with PD [15]. Our
ﬁndings therefore support the contribution of hypertensive
microangiopathy as the underlying etiology of MPS, which might
be a preventable syndrome.
As expected, we also found that age, history of stroke, as well as
mixed [basal ganglia and thalamus] LIs, were signiﬁcantly associ-
ated with MPS, whereas the relationship between strictly thalamus
LIs, or strictly basal ganglia LIs and MPS was nonsigniﬁcant. This
suggests the impact of the basal ganglia and thalamus on MPS,
reﬂecting not only location-speciﬁc but also dose-dependent effect.
Regarding the risk of category, there were independent associ-
ations between mixed LIs, WMHs, global SVD, and gait/balance,
possibly reinforcing not only shared pathophysiology but also an
independent contribution by SVDs to gait/balance disturbance.
Moreover, the relationship between mixed LIs and bradykinesia is
in line with a previous study [3], supporting its pathophysiological
role and the vulnerability of vascular burden in the basal gan-
gliaethalamocortical circuits. However, despite independent asso-
ciations between CMBs and MPS, we were unable to demonstrate
an association between CMBs and the category of MPS, partly due
Table 1
Baseline characteristics with respect to MPS.
All (n ¼ 268) MPS () (n ¼ 137) MPS (þ) (n ¼ 131) P value
Age (years) 71.0 ± 7.8 68.8 ± 7.9 73.3 ± 7.0 <0.001
Male 168 (63) 88 (64.2) 80 (61.1) 0.59
Body mass index 23.4 ± 3.0 23.6 ± 2.9 23.1 ± 3.1 0.13
Current smoker 21 (8) 9 (7) 12 (9.1) 0.49
Hypertension 221 (82) 108 (78.8) 113 (86.2) 0.11
Systolic blood pressure (mmHg) 129.7 ± 11.1 129.6 ± 11.9 129.8 ± 10.3 0.89
Diastolic blood pressure (mmHg) 74.4 ± 9.4 74.8 ± 9.3 74.0 ± 9.5 0.51
Diabetes mellitus 76 (28) 38 (27.4) 38 (29.1) 0.82
HbA1c (NGSP) (%) 6.05 ± 0.76 6.07 ± 0.84 6.03 ± 0.68 0.70
Dyslipidemia 201 (75) 105 (76.6) 96 (73.3) 0.53
Low density lipoprotein (mg/dL) 108.9 ± 27.4 112.2 ± 27.1 105.4 ± 27.4 0.051
High density lipoprotein (mg/dL) 56.4 ± 15.8 56.3 ± 15.0 56.2 ± 16.4 0.98
Triglyceride (mg/dL) 123.1 ± 64.8 126.4 ± 59.0 119.5 ± 70.3 0.39
Coronary artery disease 27 (10) 9 (6.6) 18 (13.7) 0.07
Atrial ﬁbrillation 19 (7) 9 (6.6) 10 (7.6) 0.81
History of ischemic stroke 95 (35) 42 (30.7) 53 (40.5) 0.094
History of cerebral hemorrhage 11 (4.1) 1 (0.7) 11 (7.6) 0.004
Any CMBs 58 (21.6) 18 (13.1) 40 (30.5) 0.0005
Deep CMBs 42 (15.7) 11 (8.0) 31 (23.7) <0.001
Strictly lobar CMBs 16 (6.0) 7 (5.1) 9 (6.8) 0.41
Any LIs 106 (39.6) 47 (34.3) 59 (45.4) 0.07
LIs in basal ganglia 62 (23.1) 31 (22.6) 31 (23.7) 0.84
LIs in thalamus 11 (4.1) 5 (3.7) 6 (4.6) 0.70
Mixed LIs: in basal ganglia and thalamus 16 (6.0) 2 (1.5) 14 (10.7) 0.0014
PVH 3 (2e5) 2 (1e4) 4 (2e5) <0.001
DWMH 6 (2e8) 4 (1e7) 7 (4e10) <0.001
Total SVD 1 (0e2) 0 (0e1) 1 (0e2) <0.001
Data represent number (percentage), mean ± standard deviation, or median (interquartile range). P values were calculated by univariate analysis.
Abbreviation: MPS, mild parkinsonian signs; CMBs, cerebral microbleeds; LIs, lacunar infarctions; PVH, periventricular hyperintensities; DWMH, deep white matter
hyperintensities.
Fig. 2. Association between the presence of MPS and SVD. Logistic regression analysis was used to estimate the association between MPS and each SVD (CMBs [any, deep, and
strictly lobar], LIs [strictly basal ganglia, strictly thalamus, mixed (basal ganglia and thalamus)], PVH, DWMH and total SVD: adjusted for age, sex, intervals of MRI (duration between
baseline examination and brain MRI), hypertension, diabetes mellitus, dyslipidemia, and history of stroke. Abbreviation: MPS, mild parkinsonian signs; SVD, small vessel disease;
CMBs, cerebral microbleeds; LIs, lacunar infarctions; PVH, periventricular hyperintensities; DWMH, deep white matter hyperintensities; OR, odds ratio; 95%CI, 95% conﬁdence
interval.
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We have not introduced simultaneous adjustment for SVD toavoid possible mediating effects, because each SVD often occur
together and are highly correlated, despite different pathogenic
Table 2
Association between the presence of each category of UPDRS and each SVD which conﬁrmed signiﬁcant association with MPS.
Bradykinesia Rigidity Gait/balance
Any CMBs 0.95 (0.35e2.41)
0.93
0.69 (0.36e1.34)
0.28
2.07 (0.80e5.18)
0.131
Deep CMBs 0.87 (0.28e2.40)
0.79
0.53 (0.25e1.10)
0.09
2.09 (0.73e5.79)
0.17
Mixed LIs (in basal ganglia and thalamus) 3.72 (1.08e11.9)*
0.037
0.75 (0.25e2.29)
0.62
4.33 (1.10e15.99)* 0.037
PVH 1.18 (0.93e1.50)
0.170
1.18 (1.01e1.38)*
0.033
1.29 (1.00e1.69)*
0.049
DWMH 1.09 (0.97e1.19)
0.054
1.05 (0.99e1.12)
0.079
1.10 (1.01e1.21)*
0.028
Total SVD 1.00 (0.68e1.45)
0.98
1.16 (0.90e1.49)
0.25
1.65 (1.14e2.40)*
0.008
OR (95%CI) and P values were calculated by logistic regression analysis adjusted for age, sex, hypertension, diabetes mellitus, dyslipidemia, and history of stroke.
Abbreviation: UPDRS, Uniﬁed Parkinson's Disease Rating Scale; MPS, mild parkinsonian signs; SVD, small vessel disease; CMBs, cerebral microbleeds; LIs, lacunar infarctions;
PVH, periventricular hyperintensities; DWMH, deep white matter hyperintensities; OR, odds ratio; 95%CI, 95% conﬁdence interval.
*p < 0.05.
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these associations can be attributed to a direct effect of individual
SVD features or to the accompanying SVD burden, we tested the
effect of total SVD score on MPS. The score might provide a po-
tential impact of SVD than each of the SVD separately. Our ﬁndings
therefore may indicate a more widespread disruption of neuronal
networks in subjects with MPS.
Indeed, imaging and pathological cross-sectional studies
showed that there was a signiﬁcant association among the size of
WMH, and LIs with MPS, suggesting that cerebrovascular pathol-
ogies may play an important role in the etiology of MPS [2,3,16].
However, longitudinal clinical studies investigating the predictive
value of combined assessment of both SVD and MPS in the devel-
opment of incident parkinsonism are currently lacking. Only one
recent prospective study supports by providing robust evidence
that the relation between SVD at baseline and incident parkin-
sonism, which showed that a high WMH volume, multiple LIs, and
CMBs were associated with an increased 5-year risk of any
parkinsonism (n ¼ 20) (including vascular parkinsonism [n ¼ 15])
[5]. Furthermore, they reported a relatively high incidence of
parkinsonism, compared to population-based studies, which may
also indicate that individuals with a high SVD burden had an
increased risk of parkinsonism [5]. Furthermore, these aforemen-
tioned associations are indirectly supported by several studies in
patients with PD. Comorbid WMH has been associated with gait/
balance impairment in PD, probably independently from the de-
gree of nigrostriatal dopaminergic denervation [17]. Given these
accumulating evidences, SVD appeared to be important in the
development of MPS and parkinsonism, which might be a pre-
ventable syndrome in patients with risk factors for SVD. Generally,
MPS are common in the elderly not showing neurological disease
and associated with signiﬁcant morbidity, mortality and dementia.
However, only a few studies have aimed at evaluating potential risk
factors for MPS and it was not elucidated sufﬁciently whether MPS
share the same risk factors as harbinger of PD or whether the
occurrence of MPS might largely be associated with vascular risk
related to aging. Due to the fact that the pathological features of PD
are relatively uncommon in the elderly rather than cerebrovascular
pathologies, they cannot account for the full spectrum of MPS.
Furthermore, we are not aware of previous prospective study
exploring the association between the progression of SVD burden
and progression to a higher category of MPS (from normal to MPS,
and from MPS to parkinsonism). So far, the exact and direct role of
both SVD and MPS in the development of PD is unknown. However,
we might be able to investigate this in our follow-up study. Future
longitudinal studies are needed to assess to what extent MPS is apredictive marker of the subsequent of distinct parkinsonism.
This study has several limitations. First, although the UPDRS
motor scoring is a generally and widely used test for the evaluation
of MPS, it is sometimes difﬁcult to distinguish clinically, especially
in the elderly. Multiple cerebral and systemic disorders can inﬂu-
ence the UPDRS scores,making it difﬁcult to tease out the individual
effects of each. For themultivariate analysis, we adjusted the history
of stroke as a confounder. Moreover, we tried to overcome this
problem by having experienced neurologists evaluate all subjects.
After review by the panel, these diagnoses were conﬁrmed. How-
ever, despite careful diagnostic workup, some loss of precision is
possible, which might lead to underestimation of the association.
Second, the cross-sectional design limits causal inferences. Third,
our study was limited to a cohort of Japanese individuals with
vascular proﬁles and concomitant SVD burden, and hence, our re-
sults may not be generalizable to other races and cohorts. Finally,
we did not investigate a detailed neuropsychological examination
of global cognition or depressive symptoms, which are unlikely to
be precise estimates of the true prevalence of cognition or depres-
sion; hence, this might have attenuated the expected association.
Our ﬁndings suggest that SVD, including deep CMBs, and in
particular, the total SVD score, might be an intermediate marker for
MPS, especially gait/balance function. Hence, although the treat-
ment of SVD is still limited and empirical, strategic efforts should be
made at least to prevent the progression of SVD through rigorous
management of vascular risk factors at midlife, and in turn reduce
the risk of motor disturbance in late life. It might also be plausible
that an effective control of vascular risk in patients who already
have SVD will help reduce the severity of the microvascular pa-
thology, and thereby, mitigate the risk of motor disturbance.
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